FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1566338804> ?p ?o ?g. }

• W1566338804 endingPage "3951" @default.
• W1566338804 startingPage "3943" @default.
• W1566338804 abstract "BACKGROUND The authors have previously reported 2 consecutive phase 2 trials in patients with early breast cancer that overexpresses human epidermal growth factor receptor 2 ( HER2 ) to assess the feasibility of incorporating anti‐HER2 therapies into dose‐dense (dd) chemotherapy regimens. The incidence of congestive heart failure (CHF) at a median follow‐up of 2 years was 1.4% and 3.2%, respectively. METHODS In trial A, patients received dd doxorubicin and cyclophosphamide (AC)→paclitaxel (T) (each given every 2 weeks) × 4 with trastuzumab (H) given × 1 year. In trial B, weekly T (weekly × 12) was substituted for ddT and lapatinib × 1 year was added. Herein, the authors report the longer‐term incidence of CHF and distant disease‐free survival (DDFS). RESULTS From January 2005 to May 2008, 165 patients enrolled (median age, 46 years, with a median left ventricular ejection fraction of 68% [range, 52%‐81%]), 17%of whom had previous hypertension. With a median follow‐up of 84 months (trial A) and 57 months (trial B), 1 additional patient developed CHF. Therefore, the cumulative incidence of CHF was 1.4% (95% confidence interval [95% CI], 1.36%‐7.7%) for trial A and 4.2% (95% CI, 4.2%‐10.4%) for trial B. The 5‐year DDFS for trials A and B was 92% (95% CI, 83%‐97%) and 89% (95% CI, 81%‐94%), respectively. CONCLUSIONS Longer follow‐up of these 2 studies has demonstrated that ddAC→TH only or with lapatinib is associated with a low risk of CHF and promising DDFS in patients with early breast cancer. Cancer 2013 ;119:3943–3951. © 2013 American Cancer Society ." @default.
• W1566338804 created "2016-06-24" @default.
• W1566338804 creator A5001265699 @default.
• W1566338804 creator A5002918170 @default.
• W1566338804 creator A5035950254 @default.
• W1566338804 creator A5039225060 @default.
• W1566338804 creator A5047713528 @default.
• W1566338804 creator A5049174232 @default.
• W1566338804 creator A5056374636 @default.
• W1566338804 creator A5060188343 @default.
• W1566338804 creator A5062030620 @default.
• W1566338804 creator A5067642403 @default.
• W1566338804 creator A5068207600 @default.
• W1566338804 creator A5069656105 @default.
• W1566338804 creator A5070245248 @default.
• W1566338804 creator A5072128358 @default.
• W1566338804 creator A5078465445 @default.
• W1566338804 date "2013-08-26" @default.
• W1566338804 modified "2023-10-17" @default.
• W1566338804 title "Long‐term cardiac safety and outcomes of dose‐dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer" @default.
• W1566338804 cites W1966456411 @default.
• W1566338804 cites W1984361364 @default.
• W1566338804 cites W1991697331 @default.
• W1566338804 cites W1997127252 @default.
• W1566338804 cites W1998554650 @default.
• W1566338804 cites W2014166418 @default.
• W1566338804 cites W2045806344 @default.
• W1566338804 cites W2049359323 @default.
• W1566338804 cites W2053541767 @default.
• W1566338804 cites W2096864872 @default.
• W1566338804 cites W2096884232 @default.
• W1566338804 cites W2098775844 @default.
• W1566338804 cites W2099562503 @default.
• W1566338804 cites W2100540244 @default.
• W1566338804 cites W2101760255 @default.
• W1566338804 cites W2105436256 @default.
• W1566338804 cites W2111578514 @default.
• W1566338804 cites W2123591186 @default.
• W1566338804 cites W2125239609 @default.
• W1566338804 cites W2125620887 @default.
• W1566338804 cites W2130936824 @default.
• W1566338804 cites W2136166698 @default.
• W1566338804 cites W2137159389 @default.
• W1566338804 cites W2140074016 @default.
• W1566338804 cites W2143967622 @default.
• W1566338804 cites W2144124503 @default.
• W1566338804 cites W2146384083 @default.
• W1566338804 cites W2149908785 @default.
• W1566338804 cites W2152121934 @default.
• W1566338804 cites W2164097569 @default.
• W1566338804 cites W2165160601 @default.
• W1566338804 cites W2166572860 @default.
• W1566338804 cites W2169281409 @default.
• W1566338804 doi "https://doi.org/10.1002/cncr.28284" @default.
• W1566338804 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24037735" @default.
• W1566338804 hasPublicationYear "2013" @default.
• W1566338804 type Work @default.
• W1566338804 sameAs 1566338804 @default.
• W1566338804 citedByCount "18" @default.
• W1566338804 countsByYear W15663388042014 @default.
• W1566338804 countsByYear W15663388042015 @default.
• W1566338804 countsByYear W15663388042016 @default.
• W1566338804 countsByYear W15663388042017 @default.
• W1566338804 countsByYear W15663388042019 @default.
• W1566338804 countsByYear W15663388042020 @default.
• W1566338804 countsByYear W15663388042021 @default.
• W1566338804 countsByYear W15663388042022 @default.
• W1566338804 crossrefType "journal-article" @default.
• W1566338804 hasAuthorship W1566338804A5001265699 @default.
• W1566338804 hasAuthorship W1566338804A5002918170 @default.
• W1566338804 hasAuthorship W1566338804A5035950254 @default.
• W1566338804 hasAuthorship W1566338804A5039225060 @default.
• W1566338804 hasAuthorship W1566338804A5047713528 @default.
• W1566338804 hasAuthorship W1566338804A5049174232 @default.
• W1566338804 hasAuthorship W1566338804A5056374636 @default.
• W1566338804 hasAuthorship W1566338804A5060188343 @default.
• W1566338804 hasAuthorship W1566338804A5062030620 @default.
• W1566338804 hasAuthorship W1566338804A5067642403 @default.
• W1566338804 hasAuthorship W1566338804A5068207600 @default.
• W1566338804 hasAuthorship W1566338804A5069656105 @default.
• W1566338804 hasAuthorship W1566338804A5070245248 @default.
• W1566338804 hasAuthorship W1566338804A5072128358 @default.
• W1566338804 hasAuthorship W1566338804A5078465445 @default.
• W1566338804 hasBestOaLocation W15663388041 @default.
• W1566338804 hasConcept C121608353 @default.
• W1566338804 hasConcept C126322002 @default.
• W1566338804 hasConcept C141071460 @default.
• W1566338804 hasConcept C143998085 @default.
• W1566338804 hasConcept C151032500 @default.
• W1566338804 hasConcept C2776694085 @default.
• W1566338804 hasConcept C2776755627 @default.
• W1566338804 hasConcept C2777292972 @default.
• W1566338804 hasConcept C2777329042 @default.
• W1566338804 hasConcept C2778198053 @default.
• W1566338804 hasConcept C2779786085 @default.
• W1566338804 hasConcept C2911091166 @default.
• W1566338804 hasConcept C44249647 @default.
• W1566338804 hasConcept C530470458 @default.

• next